Oncolyze Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Crowdfunding
- (Cancelled)
Oncolyze General Information
Description
Provider of biotherapeutics services intended to treat cancer. The company develops anti-cancer drugs that combine suitably well with chemotherapy and finds a cancer-specific protein that sits on the external surface of nearly all cancer cells but not normal cells and anchors, the active piece pokes holes in the surface, killing the cancer cell almost instantly, enabling cancer patients to get relief from painful treatments and increase their chances of surviving.
Contact Information
Website
www.oncolyze.comCorporate Office
- 845 Un Plaza, Apartment 61B
- New York, NY 10017
- United States
Corporate Office
- 845 Un Plaza, Apartment 61B
- New York, NY 10017
- United States
Oncolyze Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Equity Crowdfunding | 01-Jul-2022 | Cancelled | Clinical Trials - General | |||
4. Later Stage VC (Series A) | 06-Jul-2022 | Completed | Clinical Trials - General | |||
3. Seed Round | 30-Jun-2018 | Completed | Clinical Trials - General | |||
2. Seed Round | 07-Jan-2014 | $1.1M | $1.25M | Completed | Clinical Trials - General | |
1. Seed Round | 31-Dec-2013 | $155K | $155K | Completed | Clinical Trials - General |
Oncolyze Patents
Oncolyze Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230346708-A1 | Stable formulations of anti-cancer peptides | Pending | 06-Jan-2020 | ||
EP-3773660-A4 | Compositions for use in lysis of selective cancer cells | Pending | 08-Apr-2019 | ||
AU-2020225275-A1 | Hdm2 antibody for use in treating cancer | Pending | 20-Feb-2019 | ||
EP-3927362-A4 | Hdm2 antibody for use in treating cancer | Pending | 20-Feb-2019 | ||
EP-3927362-A1 | Hdm2 antibody for use in treating cancer | Pending | 20-Feb-2019 | C07K16/32 |
Oncolyze Executive Team (7)
Name | Title | Board Seat |
---|---|---|
Steven Evans MD | Co-Founder, Chief Executive Officer and Board Member | |
Barbara Carlin | Chief Financial Officer | |
Aleksandar Stojanovic MD | Chief Operating Officer | |
Larry Altstiel Ph.D | Chief Scientific Officer | |
John Abeles MD | Co-Founder, Board Member & Chief Corporate Development and Strategy Officer |
Oncolyze Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
Alexander Zukiwski MD | Self | Clinical Advisor and Board Member | |
James Foght Ph.D | Self | Board Member and Business Advisor | |
John Abeles MD | Oncolyze | Co-Founder, Board Member & Chief Corporate Development and Strategy Officer | |
Rosemary Mazanet Ph.D | Self | Board Member and Clinical Advisor | |
Steven Evans MD | Oncolyze | Co-Founder, Chief Executive Officer and Board Member |
Oncolyze Signals
Oncolyze FAQs
-
When was Oncolyze founded?
Oncolyze was founded in 2011.
-
Who is the founder of Oncolyze?
Steven Evans MD and John Abeles MD are the founders of Oncolyze.
-
Who is the CEO of Oncolyze?
Steven Evans MD is the CEO of Oncolyze.
-
Where is Oncolyze headquartered?
Oncolyze is headquartered in New York, NY.
-
What is the size of Oncolyze?
Oncolyze has 5 total employees.
-
What industry is Oncolyze in?
Oncolyze’s primary industry is Therapeutic Devices.
-
Is Oncolyze a private or public company?
Oncolyze is a Private company.
-
What is Oncolyze’s current revenue?
The current revenue for Oncolyze is
. -
How much funding has Oncolyze raised over time?
Oncolyze has raised $3.27M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »